Business
mCig, Inc. Enters Rapidly Growing CBD Pet Products Industry
mCig, Inc. Enters Rapidly Growing CBD Pet Products Industry.
About this update from Bots Inc.
[{"type":"text","content":"\n\n With a Visionary Doctor on Board, mCig, Inc. Moves Forward with a CBD-Based Product Line for Pets.\n JACKSONVILLE, FL, Jan. 29, 2018 (GLOBE NEWSWIRE) -- mCig, Inc. (OTCQB: MCIG), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research, and development, nutraceuticals and pharmaceuticals, today has announced plans to launch an innovatively advanced hemp CBD-based formula for pets. Doctor of Bioengineering and Cardiology at Mt. Sinai Medical Center, Arkady Uryash, will be leading this new initiative in the rapidly expanding sixty-billion-dollar CBD pet industry market. “CBD-based pet products are seeing heightened demand across the globe. Trial studies have shown that CBD oils can help reduce anxiety, inflammation, and chronic pain while boosting the pet’s immune system,” Says Arkady Uryash, MD, Ph.D. at Biomedical Research Institute, Mt Sinai Medical Center. “Results have demonstrated rapid positive results in improving condition of pets suffering from these ailments, which is one of the many reasons pet owners are eager to obtain CBD wellness products supported by science and from reputable and trustworthy companies.” The decision to expand into the pet products industry was based on extensive research conducted on customer and supplier inquiries. Comparison of research on how cannabinoids (including CBD) affects the human and animal body has shown that their effects share close similarities in interaction with endocannabinoid system (ECS).  Dogs and Cats were specifically found to share up to 70% biological homology with humans. Highly promising scientific conclusions indicate that CBD interacts in a similar way in canines and felines as it does in humans. Specifically, cannabinoid binding to ECS receptors within the dog and cat body can provide a longer lasting therapeutic effect without a risk of toxicity. The findings also revealed that major competing CBD pet market producers of edible liquid and chewable products pressed to increase the CBD concentration due to degradation and low final levels in pets. High doses can be overwhelming for small pets, therefore, these edibles cannot be used on cats or small dogs. Subsequently, most competitor’s pet products do not get verified in regards to safe levels of pesticides, herbicides, heavy metals,...